Cardiopulmonary Stress Testing Systems Global Market Report 2024

The cardiopulmonary stress testing systems market size has grown strongly in recent years. It will grow from $5.06 billion in 2023 to $5.43 billion in 2024 at a compound annual growth rate (CAGR) of 7.2%. The expansion observed during the historical period can be attributed to several factors, including an increase in the prevalence of cardiovascular and respiratory diseases, demographic shifts leading to an aging population, ongoing development of healthcare infrastructure, heightened awareness and prevention initiatives, and the influence of reimbursement policies and healthcare spending on diagnostic testing practices.

The cardiopulmonary stress testing systems market size is expected to see steady growth in the next few years. It will grow to $6.81 billion in 2028 at a compound annual growth rate (CAGR) of 5.8%. Forecasted growth is driven by personalized medicine, remote monitoring, preventive care, population health initiatives, and emerging market expansion. Trends include wireless tech integration, portable diagnostics, software advancements, preventive focus, telehealth expansion, AI integration, and novel testing protocols.

The escalating prevalence of cardiovascular diseases (CVDs) is anticipated to drive significant growth within the cardiopulmonary stress testing systems market in the foreseeable future. CVDs encompass a spectrum of disorders impacting the heart and blood vessels, with factors such as unhealthy dietary habits, sedentary lifestyles, and urbanization contributing to their increasing prevalence. Cardiopulmonary stress testing systems play a pivotal role in evaluating cardiovascular health by assessing cardiac and pulmonary function during exercise, offering valuable insights for tailoring individualized exercise programs based on a patient's functional capacity and cardiovascular constraints. Data from the Centers for Disease Control and Prevention (CDC) underscores the magnitude of the issue, with approximately 48% of adults in the United States afflicted by some form of cardiovascular disease, including an estimated 12.5 million individuals suffering from coronary artery disease (CAD). Consequently, the burgeoning prevalence of cardiovascular diseases emerges as a primary driver propelling the expansion of the cardiopulmonary stress testing systems market.

Prominent players within the cardiopulmonary stress testing systems market are actively engaged in developing innovative solutions, such as portable electrocardiogram (ECG) devices, to bolster market revenues and meet evolving consumer needs. Portable ECG devices enable the convenient recording of the heart's electrical activity on-the-go, enhancing accessibility to cardiac monitoring and facilitating early detection of cardiovascular abnormalities. For instance, AliveCor, a leading US-based medical device and AI company, introduced the KardiaMobile Card in February 2022 - a groundbreaking, credit-card-sized personal ECG device. Slim enough to fit into a wallet, the KardiaMobile Card delivers a medical-grade, single-lead ECG within 30 seconds, empowering users with the ability to detect various heart conditions, including atrial fibrillation (AFib), bradycardia, and tachycardia. Endorsed by the FDA, this innovative device exemplifies a paradigm shift in cardiac monitoring, offering unparalleled convenience and accuracy in detecting cardiovascular abnormalities. By leveraging cutting-edge technology, portable ECG devices such as the KardiaMobile Card underscore the commitment of major industry players to advancing cardiac diagnostics and improving patient outcomes in the fight against cardiovascular diseases.

In August 2021, Hill-Rom, a medical device company headquartered in the United States, completed the acquisition of Bardy Diagnostics Inc. for $375 million. This strategic acquisition was aimed at strengthening Hill-Rom's connected care portfolio and augmenting its existing cardiology lineup. This includes devices such as cardiac stress exercise, holter, and resting ECG devices. Bardy Diagnostics Inc., based in the United States, specializes in the manufacture of cardiology-related devices, including stress testing systems.

Major companies operating in the cardiopulmonary stress testing systems market report are Cardinal Health Inc., General Electric, Thermo Fisher Scientific Ltd., Siemens Healthineers AG, Becton Dickinson and Co., Koninklijke Philips N.V., GE Healthcare, Hill-rom Holdings Inc., Masimo Corporation, Halma plc, Nihon Kohden Corporation, OSI Systems Inc., Welch Allyn, Fukuda Denshi Co. Ltd., Spacelabs Healthcare, Schiller AG, Vyaire Medical Inc., Nonin Medical Inc., MGC Diagnostic Corporation, SunTech Medical Inc., COSMED srl, Allengers Medical Systems Ltd., Nasiff Associates Inc., CareFusion Corporation (BD), Clarity Medical.

North America was the largest region in the cardiopulmonary stress testing systems market in 2023. The regions covered in the cardiopulmonary stress testing systems market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cardiopulmonary stress testing systems market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cardiopulmonary stress testing systems serve as advanced diagnostic tools within healthcare settings, designed to assess the performance of both the cardiovascular and respiratory systems under stress conditions. These tests play a crucial role in developing personalized exercise regimens, evaluating the efficacy of treatments, and forecasting prognoses for patients with cardiovascular and respiratory ailments.

Key product types of cardiopulmonary stress testing systems include cardiopulmonary exercise testing (CPET) systems, stress electrocardiograms (ECG), pulse oximeters, single-photon emission computed tomography (SPECT), and stress blood pressure monitors. CPET systems, in particular, are utilized to comprehensively assess the cardiovascular and pulmonary efficiency of patients. These systems measure parameters such as oxygen uptake, carbon dioxide production, minute ventilation, and anaerobic thresholds. They find application across various healthcare settings including hospitals, specialty clinics (especially cardiology clinics), ambulatory surgical centers, and diagnostic centers.

The cardiopulmonary stress testing systems market research report is one of a series of new reports that provides cardiopulmonary stress testing systems market statistics, including cardiopulmonary stress testing systems industry global market size, regional shares, competitors with a cardiopulmonary stress testing systems market share, detailed cardiopulmonary stress testing systems market segments, market trends and opportunities, and any further data you may need to thrive in the cardiopulmonary stress testing systems industry. This cardiopulmonary stress testing systems market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cardiopulmonary stress testing systems market consists of sales of specialized systems, metabolic carts, and portable devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.